Literature DB >> 30627816

Cortical atrophic-hypometabolic dissociation in the transition from premanifest to early-stage Huntington's disease.

Frederic Sampedro1,2,3, Saul Martínez-Horta1,2,3,4, Jesús Perez-Perez1,2,3,4,5, Andrea Horta-Barba1,2,4, Diego Alfonso Lopez-Mora6, Valle Camacho6, Alejandro Fernández-León6, Beatriz Gomez-Anson5,7, Ignasi Carrió5,6, Jaime Kulisevsky8,9,10,11,12.   

Abstract

PURPOSE: Huntington's disease (HD) is a fatal neurodegenerative disorder with no effective treatment currently available. Although the pathological hallmark of HD is massive striatal atrophy, it has been suggested that cortical deterioration may concomitantly occur and play a major role in the patient's functional independence. Our objective was to characterize cortical structural and metabolic neurodegeneration in the transition from premanifest to early-stage Huntington's disease (HD).
METHODS: Using a surface-based neuroimaging approach, we compared cortical thickness and intracortical FDG-PET uptake in 19 early-symptomatic HD patients with respect to 21 premanifest HD individuals.
RESULTS: Early-HD patients showed significant cortical atrophy and intracortical hypometabolism when compared to premanifest subjects (p < 0.05, corrected for multiple comparisons). However, whereas the atrophy pattern was restricted to precentral and parieto-occipital regions, a pronounced frontotemporal hypometabolism was observed. Importantly, structural changes correlated with motor and cognitive performance, and metabolic changes were associated with the presence and severity of apathy in this population, a core neuropsychiatric feature of this disorder.
CONCLUSION: Our findings reveal an asynchronous neuronal loss and metabolic compromise across the cerebral cortex in early HD. Hence, the use of structural and metabolic imaging indicators to characterize disease progression in this population should take into consideration the dissociation which occurs between cortical atrophy and hypometabolism.

Entities:  

Keywords:  18F-FDG-PET; Cortical thickness; Huntington’s disease; Partial volume correction

Mesh:

Year:  2019        PMID: 30627816     DOI: 10.1007/s00259-018-4257-z

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  23 in total

1.  EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2.

Authors:  Andrea Varrone; Susanne Asenbaum; Thierry Vander Borght; Jan Booij; Flavio Nobili; Kjell Någren; Jacques Darcourt; Ozlem L Kapucu; Klaus Tatsch; Peter Bartenstein; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-12       Impact factor: 9.236

2.  Huntington's disease: effect of memantine on FDG-PET brain metabolism?

Authors:  Lena Elisabeth Hjermind; Ian Law; Aia Jønch; Jette Stokholm; Jørgen Erik Nielsen
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2011       Impact factor: 2.198

3.  Regional and progressive thinning of the cortical ribbon in Huntington's disease.

Authors:  H D Rosas; A K Liu; S Hersch; M Glessner; R J Ferrante; D H Salat; A van der Kouwe; B G Jenkins; A M Dale; B Fischl
Journal:  Neurology       Date:  2002-03-12       Impact factor: 9.910

4.  Cerebral cortex structure in prodromal Huntington disease.

Authors:  Peggy C Nopoulos; Elizabeth H Aylward; Christopher A Ross; Hans J Johnson; Vincent A Magnotta; Andrew R Juhl; Ronald K Pierson; James Mills; Douglas R Langbehn; Jane S Paulsen
Journal:  Neurobiol Dis       Date:  2010-08-02       Impact factor: 5.996

Review 5.  Huntington's disease: from molecular pathogenesis to clinical treatment.

Authors:  Christopher A Ross; Sarah J Tabrizi
Journal:  Lancet Neurol       Date:  2011-01       Impact factor: 44.182

6.  Measuring the thickness of the human cerebral cortex from magnetic resonance images.

Authors:  B Fischl; A M Dale
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

7.  Behavioural problems in Huntington's disease using the Problem Behaviours Assessment.

Authors:  Elisabeth M Kingma; Erik van Duijn; Reinier Timman; Rose C van der Mast; Raymund A C Roos
Journal:  Gen Hosp Psychiatry       Date:  2008 Mar-Apr       Impact factor: 3.238

8.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

9.  Neuropsychological correlates of brain atrophy in Huntington's disease: a magnetic resonance imaging study.

Authors:  S E Starkstein; J Brandt; F Bylsma; C Peyser; M Folstein; S E Folstein
Journal:  Neuroradiology       Date:  1992       Impact factor: 2.804

10.  Cognitive and cerebral metabolic effects of celecoxib versus placebo in people with age-related memory loss: randomized controlled study.

Authors:  Gary W Small; Prabha Siddarth; Daniel H S Silverman; Linda M Ercoli; Karen J Miller; Helen Lavretsky; Susan Y Bookheimer; S-C Huang; Jorge R Barrio; Michael E Phelps
Journal:  Am J Geriatr Psychiatry       Date:  2008-12       Impact factor: 4.105

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.